Breaks Categories: News

WednesdayJul 16, 2025 12:24 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress

  Lantern Pharma (NASDAQ: LTRN), a biotech company leveraging its RADR(R) AI platform to accelerate precision oncology drug development, has engaged IBN to lead its corporate communications strategy. With clinical programs targeting lung, brain, breast, and blood cancers—including three AI-guided candidates and a CNS-focused subsidiary—Lantern is advancing multiple FDA-designated therapies in active trials. The partnership with IBN aims to expand investor awareness as Lantern pursues key milestones across its data-driven, biomarker-informed pipeline. To view the full press release, visit https://ibn.fm/4jRwm About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug…

Continue Reading

TuesdayJul 15, 2025 2:30 pm

BioMedNewsBreaks – Zacks Research Releases Updated Report as Soligenix Inc. (NASDAQ: SNGX) Eyes Upcoming ‘Key Catalysts’

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research report that presented a favorable analysis, noting that the company is anticipating a number of key catalysts in the second half of 2025, including progress on its current phase 3 FLASH2 trial of HyBryte(TM) for the treatment of early-stage cutaneous T cell lymphoma (“CTCL”). According to the report, Soligenix is developing products to treat rare diseases within two business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics business segment currently has multiple products under development, and the report noted…

Continue Reading

TuesdayJul 15, 2025 11:20 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to one-third. The platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib. Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications. To…

Continue Reading

FridayJul 11, 2025 9:00 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines 

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company's initial focus, it is also evaluating applications in autoimmune disorders, underscoring its broader therapeutic potential. The editorial emphasizes Calidi’s role in addressing the rising global cancer burden and advancing transformative treatment options.  To view the full press release, visit: https://ibn.fm/tRB9D About Calidi Biotherapeutics  Calidi Biotherapeutics is a clinical-stage immuno-oncology…

Continue Reading

ThursdayJul 10, 2025 11:37 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In exchange, the company will issue new unregistered warrants with the same share count, exercisable in six months at $0.70 and valid for five and a half years. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. Calidi plans to use the net proceeds…

Continue Reading

ThursdayJul 10, 2025 9:30 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Completes Historic REVIVE Trial, Sets Stage for Long COVID Breakthrough and Market Expansion 

Fifty 1 Labs (OTC: FITY), through its subsidiary Fifty1 AI Labs, LLC, announced the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967), a groundbreaking Phase III study and the largest Long COVID trial to date. Conducted with global partners and top institutions including Stanford and Duke, the randomized, double-blind trial enrolled over 600 participants and demonstrated a clear treatment benefit using repurposed medicines. Powered by FITY’s proprietary AI platform, the trial sets a new standard in drug repurposing and personalized medicine, while supporting the company’s broader strategy to lead the $320.6 billion functional medicine market, pursue strategic acquisitions, and…

Continue Reading

WednesdayJul 09, 2025 11:31 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment 

  CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on treating primary and metastatic cancers in the brain and central nervous system, announced CEO John Climaco’s participation in a Virtual Investor CEO Connect segment. Climaco provided an overview of the Company’s lead candidate, TPI 287, and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, Massachusetts. To view the full press release, visit https://ibn.fm/9Trwm About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.…

Continue Reading

WednesdayJul 09, 2025 9:00 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities…

Continue Reading

TuesdayJul 08, 2025 12:18 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform 

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer. To view the full press release, visit: https://ibn.fm/nMiOZ About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed…

Continue Reading

TuesdayJul 08, 2025 9:30 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Launches Bold AI-Driven Strategy to Reach $50 Million Valuation and Target NASDAQ Uplisting 

Fifty 1 Labs (OTC: FITY), a Nevada-based innovator in AI-driven drug repurposing and functional medicine, unveiled a strategic “Game Plan” aimed at achieving a $50 million valuation and uplisting to the OTCQB by Q1 2026, with long-term plans to join the NASDAQ Capital Market. Backed by a $350,000 insider investment and leadership salary deferrals, FITY is advancing its wholly owned subsidiary, Fifty1 AI Labs LLC, with a $1 million R&D initiative to discover repurposed treatments by May 2026. The company will launch a digital platform by July 31, 2025, pursue biotech acquisitions in the $5–10 million range, and host a…

Continue Reading